said Ethan Leonard, vice president of pediatric nutrition for Martek.
Columbia, MD (Vocus) December 11, 2009
Martek Biosciences Corporation (NASDAQ: MATK) announced today that it has entered into a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited for the use of Martek’s products in Fonterra’s infant formulas and milk-based Anmum™ Materna products for pregnant and nursing mothers.
Fonterra’s infant formulas, featuring life’sDHA™ and life’sARA™, will be available in Malaysia, Indonesia and China.
Fonterra’s Anmum™ Materna products for pregnant and nursing mothers, featuring life’sDHA, will be available in Indonesia, Taiwan, Hong Kong, the Philippines, Malaysia, Vietnam, Singapore, Thailand and China.
“Martek is a leading global supplier of DHA and ARA. Infant formulas containing Martek’s
life’sDHA and life’sARA can be found in more than 75 countries worldwide, and we continue to expand our international presence in the infant formula and perinatal markets,” said Ethan Leonard, vice president of pediatric nutrition for Martek. “Our sole-source supply arrangement with Fonterra further demonstrates that companies worldwide understand the importance of adding Martek’s DHA and ARA to infant formula and perinatal products for infant health and development.”
Naturally present in human breast milk, DHA (docosahexaenoic acid), and ARA (arachidonic acid) are fatty acids important to infant development and growth. Clinical studies have demonstrated numerous benefits for infants receiving DHA and ARA supplemented formula, including improved mental and visual development.
DHA also is important throughout pregnancy, particularly in the third trimester when significant brain growth occurs. Maternal DHA supplementation during pregnancy and nursing significantly enhances the level of DHA available to the fetus and infant. Studies have shown that maternal DHA supplementation may improve infant developmental outcomes, such as eye-hand coordination, motor skills and attention span.
Martek's blend of DHA and ARA, life’sDHA & life’sARA, is the only source of these nutrients currently used in U.S. infant formula, and is present in more than 95 percent of infant formula sold in the U.S. Martek’s life’sDHA can also be found around the world in a range of supplements and other products intended for use during pregnancy and breastfeeding.
Fonterra is the world’s leading exporter of dairy products and responsible for more than a third of international dairy trade. Its dairy farmers have long been known for producing quality milk and today Fonterra is a world leader in dairy commodities and premium ingredients, and has regional consumer brands businesses in Australasia, Asia, the Middle East and Latin America. Fonterra’s global supply chain stretches from farms all over New Zealand to customers and consumers in more than 140 countries. Fonterra currently manufactures the Anmum™ brand of premium milk formulas for pregnant and nursing mothers, as well as for infants and toddlers.
Martek Biosciences Corporation is a leader in the innovation and development of DHA and ARA and has developed patented technology for the production and use of these ingredients. DHA omega-3 products promote health and wellness through every stage of life and ARA omega-6 products support growth and development in infants and children. The company produces life'sDHA™, a sustainable vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, perinatal products, and supplements, and life’sARA™, a sustainable vegetarian source of ARA omega-6, for use in infant formula and growing up milks. For more information on Martek Biosciences, visit http://www.martek.com/. For more information on products containing lifesDHA and life’sARA, visit http://www.lifesdha.com.
Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.
# # #